IceCure Medical Ltd. (Nasdaq: ICCM) announced a registered direct offering of 8 million ordinary shares at $0.50 per share, expected to generate gross proceeds of approximately $4 million before fees and expenses. The offering is being made pursuant to an effective shelf registration statement on Form F‑3 (File No. 333‑290046) declared effective by the SEC on March 24, 2026, and A.G.P./Alliance Global Partners is the sole placement agent.
In addition to the share sale, the company will issue unregistered Series B and Series C warrants. Each warrant allows the holder to purchase up to 8 million ordinary shares at an exercise price of $0.55 per share. The Series B warrants are exercisable immediately and expire five years after issuance, while the Series C warrants expire one year after issuance.
The proceeds will be used for working capital and other general corporate purposes, including supporting the company’s commercial expansion and ongoing post‑market study commitments. This financing follows a Q4 2025 earnings report in which IceCure reported an EPS of –$0.06 versus an analyst consensus of –$0.04 and revenue of $1.28 million versus an estimate of $1.30 million, underscoring the company’s high burn and negative profitability.
The market reacted negatively to the announcement, reflecting concerns about dilution and the company’s financial performance. The capital raise is a critical liquidity event for a company that has recently secured FDA clearance for its ProSense® cryoablation system, a product that has opened a new revenue stream and positioned IceCure for future growth.
Management emphasized that the company is at the beginning of a favorable trend, citing the FDA clearance and record sales in the fourth quarter as evidence of growing adoption of ProSense®. The financing is intended to sustain that momentum while addressing the company’s ongoing cash needs.
Overall, the direct offering and warrant issuance represent a material capital‑raising event that provides essential liquidity, but investor concerns about dilution and the company’s current financial challenges remain prominent.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.